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Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor 
of Adverse Outcomes in COVID-19
Waqas Ullaha, d, Bikash Basyala, Shafaq Tariqa, Talal Almasb, Rehan Saeeda, Sohaib Roomia, 
 Shujaul Haqa, John Madaraa, Margot Boigona, Donald C. Haasa, David L. Fischmanc
Abstract
Background: Systemic inflammation elicited by a cytokine storm is 
considered a hallmark of coronavirus disease 2019 (COVID-19). This 
study aims to assess the validity and clinical utility of the lympho-
cyte-to-C-reactive protein (CRP) ratio (LCR), typically used for gas-
tric carcinoma prognostication, versus the neutrophil-to-lymphocyte 
ratio (NLR) for predicting in-hospital outcomes in COVID-19.
Methods: A retrospective cohort study was performed to determine 
the association of LCR and NLR with the need for invasive mechani-
cal ventilation (IMV), dialysis, upgrade to an intensive care unit (ICU) 
and mortality. Independent t-test and multivariate logistic regression 
analysis were performed to calculate mean differences and adjusted 
odds ratios (aORs) with its 95% confidence interval (CI), respectively.
Results: The mean age for NLR patients was 63.6 versus 61.6, and 
for LCR groups, it was 62.6 versus 63.7 years, respectively. The base-
line comorbidities across all groups were comparable except that the 
higher LCR group had female predominance. The mean NLR was 
significantly higher for patients who died during hospitalization (19 
vs. 7, P ≤ 0.001) and those requiring IMV (12 vs. 7, P = 0.01). Com-
pared to alive patients, a significantly lower mean LCR was observed 
in patients who did not survive hospitalization (1,011 vs. 632, P = 
0.04). For patients with a higher NLR (> 10), the unadjusted odds of 
mortality (odds ratios (ORs) 11.0, 3.6 - 33.0, P < 0.0001) and need for 
IMV (OR 3.3, 95% CI 1.4 - 7.7, P = 0.008) were significantly higher 
compared to patients with lower NLR. By contrast, for patients with 
lower LCR (< 100), the odds of in-hospital all-cause mortality were 
significantly higher compared to patients with a higher LCR (OR 0.2, 
0.06 - 0.47, P = 0.001). The aORs controlled for baseline comorbidi-
ties and medications mirrored the overall results, indicating a genu-
inely significant correlation between these biomarkers and outcomes.
Conclusions: A high NLR and decreased LCR value predict higher 
odds of in-hospital mortality. A high LCR at presentation might indi-
cate impending clinical deterioration and the need for IMV.
Keywords: COVID-19; LCR; Predictor; Adverse outcomes; NLR
Introduction
The coronavirus disease 2019 (COVID-19) is a global pan-
demic caused by the novel severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). By binding to the angiotensin-
converting enzyme 2 (ACE2) receptor, the S1 subset of the 
surface spike protein elicits the production of angiotensin 1. 
The ACE then converts angiotensin 1 to angiotensin 2, which 
in turn binds to the angiotensin receptor, upregulating the 
levels of endothelin-1 (ET-1). This results in a widespread 
inflammatory response with the release of pro-inflammatory 
cytokines and interleukins [1, 2]. The large-scale unregulated 
production of interleukins, particularly interleukin-6 (IL-6), 
stimulates several downstream pathways, increasing the pro-
duction of acute-phase reactants like C-reactive protein (CRP), 
and increases mobilization of neutrophils [3]. This, along with 
stress-induced neutrophilia, likely explains the relative lym-
phopenia seen in severe manifestations of the SARS-CoV-2 
infection [4-6].
Several studies have sought to demonstrate the clinical 
utility and feasibility of the neutrophil-to-lymphocyte ratio 
(NLR) in predicting COVID-19 outcomes [6]. A high NLR 
value at admission has been proposed as suggestive of COV-
ID-19, while confirmatory tests are pending and a rising NLR 
has been shown to be associated with worse clinical outcomes 
in severe COVID-19. While the NLR is well studied, a similar 
biomarker ratio, the lymphocyte-to-CRP ratio (LCR), has, so 
far, not been utilized. Typically, the LCR is used as a prognos-
tic marker for several types of cancers, including colon and 
gastric carcinomas [7-10]. The rationale behind this is that the 
LCR serves as a good surrogate of the complex host-tumor 
immunological interactions that result in a systemic inflam-
matory process, which is believed to contribute towards the 
pathogenesis and progression of these carcinomas [11]. Since 
COVID-19 also precipitates a systemic inflammatory response, 
it follows that the LCR may also be a good proxy marker in 
this disease process and may carry prognostic value.
The present study aims to shed light on whether LCR and 
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NLR can, in fact, be used as reliable predictors for adverse 
outcomes. We further analyzed their predictive capability by 
subdividing adverse complications and correlating the LCR 
and NLR ratios observed in each instance.
Materials and Methods
Study design and participants
This retrospective cohort study included consecutive adult 
inpatients (≥ 18 years old) from Abington Hospital-Jefferson 
Health, PA, USA. All patients had a confirmed diagnosis of 
COVID-19 between March 1, 2020 and May 10, 2020. This 
study was conducted in compliance with the ethical standards 
of the responsible institution on human subjects as well as with 
the Helsinki Declaration. The study was approved by the Insti-
tutional Review Board (IRB).
Patient and public involvement
The study was retrospective in design, data was obtained by 
chart review and there were no direct patient interactions. No 
patient was involved in the design, recruitment and conduct of 
the study. The development of research question and outcome 
measures were influenced by common inpatient outcomes for 
hospitalized patients and the results of this study will not be 
directly disseminated to study participants.
Data collection
Clinical, demographic, laboratory, treatment, and outcome 
data were extracted from electronic medical records (Sunrise) 
using a standardized data collection form. All authors contrib-
uted to data retrieval and an independent author adjudicated 
any difference in interpretation between the data extractors. 
SARS-CoV-2 was detected in respiratory specimens (throat 
swabs) by next-generation sequencing or real-time qualitative 
polymerase chain reaction (RT-qPCR) methods. The labora-
tory values, cutoff variables and methods for laboratory con-
firmation of SARS-CoV-2 infection were standardized. Data 
regarding baseline comorbidities included a history of diabe-
tes mellitus (DM), hypertension (HTN), chronic kidney dis-
ease (CKD) and coronary artery disease (CAD). In-hospital 
medications used included hydroxychloroquine (HCQ), tocili-
zumab, steroids and anticoagulation (AC). Routine blood work 
included coagulation profile, complete blood count, serum bio-
chemical tests (renal function, CRP, D-dimer, lactate dehydro-
genase (LDH), myocardial enzymes (troponin T (TnT)) and 
serum ferritin. Chest radiographs or computed tomography 
(CT) scans were also done for most inpatients where clinically 
indicated. Acute cardiac injury was diagnosed if serum levels 
of cardiac biomarkers (TnT) were above the 99th percentile 
upper reference limit in conjunction with new abnormalities 
on the electrocardiography (EKG) and transthoracic echocar-
diography (TTE). The criteria for discharge were absence of 
fever, freedom from symptoms, substantial clinical or radio-
logical improvement for at least 1 day.
Statistical analysis
Continuous variables were presented as mean and standard 
deviations (SD); categorical variables were reported in per-
centages and proportions. A Chi-square (χ2) test was used for 
comparison of categorical data; Fisher’s exact test was only 
adopted if the expected count in more than 20% cells was less 
than 5. To quantify the association between the dichotomous 
categorical variables, an unadjusted odds ratio (OR) was ob-
tained using the Cochran-Mantel-Haenszel method. To explore 
the risk factors and gauge the impact of potential effect modi-
fiers (covariates) on our endpoints (in-hospital death, need for 
an upgrade, ventilators and dialysis) binomial and multinomial 
logistic regression models were applied as appropriate. The 
differences in the baseline comorbidities (DM, HTN, CAD, 
CKD) and medication use (HCQ, tocilizumab, remdesivir, AC 
and steroids) were accounted for to obtain an adjusted odds 
ratio (aOR) for all outcomes. The Hosmer-Lemeshow (HL) 
goodness-of-fit test was used to predict the fitness of logis-
tic regression models for applicability to categorical data. For 
normally and abnormally distributed continuous data, an inde-
pendent sample t-test and Mann-Whitney U test were utilized, 
respectively. A one-way analysis of variance (ANOVA) was 
used to compare differences in the mean of continuous vari-
ables for multiple in-hospital complications. A two-sided α of 
less than 0.05 was considered statistically significant corrobo-
rating inference from a 95% confidence interval (CI). Statisti-
cal analyses were performed using the SPSS software (version 
25).
Results
Demographics and baseline characteristics
A total of 176 consecutive patients with a confirmed diagno-
sis of COVID-19 were included in our study. Patients were 
divided into two comparison groups: low NLR (< 10) versus 
high NLR (> 11), and low LCR (< 100) and high LCR (> 101). 
The mean age for NLR patients was 63.6 versus 61.6 and for 
LCR groups, it was 62.6 versus 63.7 years. The baseline co-
morbidities across all groups were comparable except that 
the higher LCR group had female predominance. The propor-
tions of underlying comorbidities between low and high NLR 
groups included DM (83.9% vs. 16.1%), HTN (86.9% vs. 
13.1%), CAD (93.1% vs. 6.1%), CKD (87.1% vs. 12.9%), and 
chronic obstructive pulmonary disease (COPD) (91.7% vs. 
8.3%) respectively. These percentages for low and high LCR 
groups were: DM (21.1% vs. 78.9%), HTN (23.0% vs. 80.0%), 
CAD (19.4% vs. 80.6%), CKD (25% vs. 75%), and COPD 
(16.7% vs. 83.3%), respectively. Patients in both NLR and 
LCR groups had similar proportions of medication use (HCQ, 
tocilizumab, AC, steroids) across both groups (P value ≥ 0.05) 
(Fig. 1, Table 1).
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Mean differences in NLR and LCR
In interventions
The mean difference in the levels of NLR and LCR between 
patients on definitive COVID-19 therapy compared to those 
not receiving therapy were mostly identical across its respec-
tive groups with few exceptions. On day 1 of presentation, the 
mean NLR for patients receiving HCQ versus no HCQ were 8 
± 9 versus 5 ± 4 (P = 0.15), tocilizumab versus no tocilizumab 
8 ± 6 versus 7 ± 9 (P = 0.84), AC versus no AC 10 ± 16 versus 
7 ± 5 (P = 0.19) and steroids versus no steroids 6 ± 5 versus 
8 ± 9 (P = 0.51), respectively. Similarly, there was no signifi-
cant difference in the post-treatment mean values of NLR in 
patients who received HCQ versus no HCQ (9 ± 11 vs. 5 ± 3, 
P = 0.28), tocilizumab versus no tocilizumab (10 ± 14 vs. 9 ± 
9, P = 0.74), and steroids versus no steroids (11 ± 14 vs. 8 ± 
9, P = 0.16) respectively. The mean NLR for patients on AC 
was significantly higher compared to the no AC group (15 ± 
17 vs. 7 ± 7, P = 0.02). The mean LCR values closely followed 
the overall trend of mean NLR ratios. The mean LCR in HCQ 
versus no HCQ was 563 ± 1,632 versus 6,820 ± 30,751 (P = 
0.28), tocilizumab versus no tocilizumab 681 ± 1,238 versus 
1,851 ± 14,221 (P = 0.64), AC versus no AC (1,117 ± 2,882 vs. 
1,759 ± 1,427, P = 0.80) and steroids versus no steroids (766 ± 
1,247 vs. 1,816 ± 1,414,122, P = 0.69) respectively. On day 7, 
the mean LCR for the patients on tocilizumab was significantly 
higher than those not on tocilizumab (2,718 ± 3,418 vs. 461 ± 
1,034, P = 0.00). The mean LCR for patients on HCQ versus 
no HCQ (918 ± 2,085 vs. 1,654 ± 1,224, P = 0.36), steroids 
versus no steroids (1,183 ± 208 vs. 893 ± 2,047, P = 0.50) and 
AC versus no AC (1,633 ± 3,094 vs. 783 ± 1,661, P = 0.18) 
were not significantly different (Fig. 2).
In outcomes
Mean differences in NLR and LCR for hard clinical outcomes 
such as in-hospital mortality and resource allocation were also 
calculated. The mean NLR and LCR differences on day 1 of 
admission were not significantly different between patients re-
quiring an upgrade (10 ± 13 vs. 6 ± 5, P = 0.06; 4,010 vs. 493, 
P = 0.25), ventilator support (9 ± 12 vs. 6 ± 5, P = 0.05; 3,675 
vs. 515, P = 0.26) and dialysis (11 ± 8 vs. 7 ± 8, P = 0.20; 712 
vs. 1,688, P = 0.82) compared to corresponding patients not re-
quiring an upgrade, ventilator and dialysis. Similarly, the mean 
difference in NLR and LCR in patients surviving compared to 
patients who died on presentation was identical (7 ± 9 vs. 9 ± 
6, P = 0.42; 1,784 vs. 474, P = 0.67), respectively. On day 7, 
higher means of NLR were associated with a higher require-
ment for invasive mechanical ventilation (IMV) (12 ± 10 vs. 
7 ± 10, P = 0.01) and increased mortality (19 ± 13 vs. 7 ± 9, 
P ≤ 0.0001). Higher mean LCR was associated with a higher 
need for an upgrade (1,784 vs. 452, P = 0.001) and IMV (1,592 
vs. 489, P = 0.01). The mean LCR for surviving patients was 
higher compared to non-surviving patients (1,011 vs. 632, P = 
0.04). (Fig. 2; Supplementary Materials 1, 2, www.jocmr.org).
In complications
In terms of in-hospital complications, patients with new-onset 
atrial fibrillation (AF) in conjunction with sepsis had the high-
est mean of NLR (27.65 ± 37.48), while patients with heart 
failure and AF had the highest mean value of LCR (8,177.46 
± 11,468.12). The detailed rates and mean values are given in 
Supplementary Materials 3, 4 (www. jocmr.org).
ORs of outcomes
On presentation, the unadjusted OR for in-hospital mortality 
(OR 1.6, 0.5 - 5.5, P = 0.63), need for upgrade to intensive 
care unit (ICU) (OR 1.7, 0.7 - 4.1, P = 0.30), and requirement 
for IMV (OR 1.5, 0.6 - 3.5, P = 0.46) and dialysis (OR 2.5, 
0.6 - 10.3, P = 0.39) were not significantly different between 
patients with high NLR (> 11) and those with low NLR. By 
contrast, the unadjusted odds for LCR served as reliable pre-
dictors for primary endpoints at presentation. High LCR (> 
101) was associated with a significantly higher odds of IMV 
and upgrade (OR 2.5, 1.3 - 5.0, P = 0.01; OR 2.9, 1.47 - 6.1, P 
= 0.004), respectively. The odds of need for dialysis (OR 1.8, 
0.4 - 7.1, P = 0.63) and mortality (OR 0.71, 0.3 - 1.8, P = 0.62) 
were identical between patients with high NLR and low NLR 
on day 1 (Tables 2, 3, Fig. 3).
On day 7 of hospitalization, high NLR was associated 
with higher odds of in-hospital mortality (OR 11.0, 3.6 - 33.0, 
P < 0.0001) and a higher requirement for IMV (OR 3.3, 1.4 - 
7.7, P = 0.008). There was no significant difference in the need 
Figure 1. Baseline characteristics of the included populations.
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for upgrade to ICU (OR 2.4, 1.0 - 5.4, P = 0.06) and dialysis 
between the two groups (OR 1.2, 0.2 - 6.1, P = 0.81). Patients 
in the low LCR group had significantly higher odds of mortal-
ity (OR 0.2, 0.06 - 0.47, P = 0.001), while there was no signifi-
cant difference in the need for an upgrade (P = 0.16), IMV (P 
= 0.21) and dialysis (0.70) between low and high LCR groups.
A multivariate regression model was used to adjust the 
observed odds ratios for baseline comorbidities and medica-
tions, including DM, HTN, CKD, CAD, use of AC at home, 
HCQ, tocilizumab, steroids and therapeutic AC during a hos-
pital stay. The adjusted odds values were consistent with unad-
justed ORs indicating no influence of covariates as shown in 
Tables 2 and 3.
Discussion
Our study reveals that a lower LCR and a high NLR could 
serve as predictive markers for in-hospital complications and 
mortality in patients with COVID-19. Compared to NLR, high 
LCR on presentation accurately predicts the in-hospital need 
for IMV and an upgrade to the ICU. During hospitalization, 
Table 1.  Baseline Characteristics of the Included Population Across Comparison Groups for Which the Pooled Estimate Were Ad-
justed
NLR < 10 NLR > 11 Significance LCR < 10 LCR > 11 Significance
Age 63.6 years 61.6 years P = 0.71 62.6 years 63.7 years P = 0.65
Sex
  Men 66 (80.50%) 16 (19.50%) P = 0.167 23 (27.70%) 60 (72.30%) P = 0.04
  Women 75 (88.20%) 10 (11.80%) 13 (14.90%) 74 (85.10%)
DM
  No 92 (85.20%) 16 (14.80%) P = 0.716 23 (21.10%) 86 (78.90%) P = 0.974
  Yes 49 (83.10%) 10 (16.90%) 13 (21.30%) 48 (78.70%)
HTN
  No 48 (80.00%) 12 (20.00%) P = 0.237 14 (23.30%) 46 (76.70%) P = 0.611
  Yes 93 (86.90%) 14 (13.10%) 22 (20.00%) 88 (80.00%)
CAD
  No 114 (82.60%) 24 (17.40%) P = 0.16 30 (21.60%) 109 (78.40%) P = 0.784
  Yes 27 (93.10%) 2 (6.90%) 6 (19.40%) 25 (80.60%)
CKD
  No 114 (83.80%) 22 (16.20%) P = 0.65 28 (20.30%) 110 (79.70%) P = 0.557
  Yes 27 (87.10%) 4 (12.90%) 8 (25.00%) 24 (75.00%)
COPD
  No 119 (83.20%) 24 (16.80%) P = 0.29 32 (21.90%) 114 (78.10%) P = 0.56
  Yes 22 (91.70%) 2 (8.30%) 4 (16.70%) 20 (83.30%)
HCQ
  No 27 (87.10%) 4 (12.90%) P = 0.65 8 (27.60%) 21 (72.40%) P = 0.354
  Yes 114 (83.80%) 22 (16.20%) 28 (19.90%) 113 (80.10%)
TM
  No 117 (84.80%) 21 (15.20%) P = 0.78 28 (20.30%) 110 (79.70%) P = 0.557
  Yes 24 (82.80%) 5 (17.20%) 8 (25.00%) 24 (75.00%)
SD
  No 115 (83.30%) 23 (16.70%) P = 0.39 32 (22.90%) 108 (77.10%) P = 0.247
  Yes 26 (89.70%) 3 (10.30%) 4 (13.30%) 26 (86.70%)
AC
  No 115 (85.80%) 19 (14.20%) P = 0.318 25 (18.40%) 111 (81.60%) P = 0.075
  Yes 26 (78.80%) 7 (21.20%) 11 (32.40%) 23 (67.60%)
DM: diabetes mellitus; HTN: hypertension; CKD: chronic kidney disease; CAD: coronary artery disease; COPD: chronic obstructive pulmonary dis-
ease; HCQ: hydroxychloroquine; TM: tocilizumab; SD: steroid; AC: anticoagulation.
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while an elevated NLR was also associated with higher odds of 
ICU upgrade and ventilatory support, a similar correlation was 
not seen with the LCR values. Even after completion of off-
label therapy for COVID-19 (HCQ, tocilizumab), a high NLR 
and low LCR were associated with significantly higher odds of 
in-hospital mortality. Based on our findings, we advocate for 
the use of LCR as a reliable predictor of the risk of in-hospital 
complications at presentation, while both high NLR and low 
LCR are useful prognostic markers for overall mortality risk. 
To the best of our knowledge, this is the first study among pa-
tients with COVID-19 identifying the potential role of LCR in 
predicting the outcomes of COVID-19.
Both NLR and LCR serve to highlight a relative lympho-
penia compared to normal or elevated neutrophil counts and 
raised CRP levels, respectively. Based on previous studies, it 
is believed that COVID-19-related widespread inflammation 
results in immune dysregulation and apoptotic loss of lym-
phocytes [12]. The coronavirus has also been demonstrated 
in circulating lymphocytes, causing a direct cytotoxic medi-
ated destruction [8, 13]. Lymphopenia, by these mechanisms, 
as well as stress-mediated neutrophilia, leads to a high NLR. 
However, the LCR may be more sensitive in capturing the ear-
ly part of the inflammatory cascade as CRP levels have been 
shown to rise earlier than either neutrophilia or lymphopenia is 
seen. Thus, a low LCR and a high NLR, which both represent 
systemic inflammation, albeit at different time frames, can be 
regarded as independent markers of in-hospital complications 
and mortality [6].
A previous meta-analysis by Lagunas-Rangel et al, on six 
studies, concluded that a rise in the NLR and decline in LCR 
might correlate with the severity of COVID-19 [13]. While 
this study has duly evaluated the prognostic ability of LCR and 
NLR for adverse post-infective outcomes, it was vastly under-
powered to stratify its results based on specific outcomes. By 
contrast, our study has determined that adjusted odds of LCR 
could be a reliable marker in the prediction for the need for 
high-level care, ventilator support and in-hospital all-cause 
mortality. Additionally, our study demonstrated that the inci-
dence of in-hospital complications is higher with a high LCR 
at presentation, while the mortality risk correlates with a high 
NLR and low LCR during hospitalization.
It is also important to note that, while high NLR is known 
to correlate with the severity of COVID-19-related compli-
cations, its utility might be limited in certain situations. For 
instance, patients on high-dose steroids can have a falsely el-
evated NLR due to the demargination of neutrophils and en-
suing neutrophilia. This is vividly demonstrated in our study, 
with a mean NLR on steroids of 11.3 ± 14, significantly higher 
than that of patients not on steroid therapy (8.2 ± 9). Similarly, 
NLR could falsely be suppressed in immunocompromised pa-
tients with neutropenia either due to the chemotherapy or bone 
marrow infiltration by the primary malignancy. LCR, in these 
situations, can serve as a reliable marker to predict the severity 
of the disease as this value is unaffected by the aforementioned 
confounders. Nonetheless, both LCR and NLR values should 
not be used as absolute indicators and require interpretation in 
the clinical context.
Early predictability of in-hospital complications can help 
in timely and effective allocation of available resources. Phy-
sicians can, therefore, adopt aggressive therapeutic measures 
in patients with initial high LCR, rising NLR and decreasing 
LCR. In the setting of a pandemic, with finite healthcare re-
sources to allocate, it is essential for providers to have robust 
and validated tools to guide where best these resources can 
be deployed. We believe that NLR and LCR when used in the 
appropriate clinical setting can play just such a role for health-
care teams by assisting early triage and guiding prognosis in 
COVID-19 patients.
Limitations
The findings of our study should be interpreted in light of its 
limitations. Due to the retrospective non-randomized nature of 
the study, a causal relationship could not be ascertained. Al-
though the overall findings were adjusted for covariates, in-
cluding baseline comorbidities and medications, the impact of 
unmeasured confounders such as initiation of several comple-
mentary therapies at the treating physician’s discretion, could 
not be determined. Based on our clinical experience, the aver-
age duration of any therapy for COVID-19 was less than 7 
days; therefore, we chose to use day 1 and day 7 laboratory 
values. However, given the variable frequency of laboratory 
specimen collection, it is not possible for us to ascertain if 
these truly represented pre- and post-treatment values accu-
rately in all cases. Moreover, by excluding patients still in the 
Figure 2. Mean NLR and LCR values at day 1 and day 7 of hospitaliza-
tion across different interventions and outcomes. NLR: neutrophil-to-
lymphocyte ratio; LCR: lymphocyte-to-C-reactive protein ratio.
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Table 2.  ORs of Outcomes in NLR Groups on Day 1 and Day 7 of Treatment
Outcomes
Day 1
N NLR < 10 NLR > 11 Unadjusted odds (P value) aOR (P value)
Vent 57 46 (81%) 11 (19%) OR 1.5 (0.6 - 3.5, P = 0.46) aOR 1.5 (0.6 - 3.7, P = 0.33)
No vent 110 95 (86%) 15 (14%)
Upgrade 53 42 (79%) 11 (21%) OR 1.7 (0.7 - 4.1, P = 0.30) aOR 1.7 (0.7 - 4.1, P = 0.24)
No upgrade 114 99 (87%) 15 (13%)
Dialysis 10 7 (70%) 3 (30%) OR 2.5 (0.6 - 10.3, P = 0.39) aOR 2.5 (0.5 - 11.2, P = 0.25)
No dialysis 157 134 (85%) 23 (15%)
Died 18 14 (78%) 4 (22%) OR 1.6 (0.5 - 5.5, P = 0.63) aOR 1.9 (0.5 - 6.7, P = 0.30)
Alive 149 127 (85%) 22 (15%)
Outcomes
Day 7
N NLR < 10 NLR > 11 Unadjusted odds (P value) aOR (P value)
Vent 55 36 (66%) 19 (34%) OR 3.3 (1.4 - 7.7, P = 0.008) aOR 3.1 (1.2 - 8.4, P = 0.024)
No vent 80 69 (86%) 11 (14%)
Upgrade 50 34 (68%) 16 (32%) OR 2.4 (1.0 - 5.4, P = 0.06) aOR 2.3 (0.9 - 6.1, P = 0.08)
No upgrade 85 71 (84%) 14 (16%)
Dialysis 8 6 (75%) 2 (25%) OR 1.2 (0.2 - 6.1, P = 0.81) aOR 0.7 (0.1 - 5.7, P = 0.73)
No dialysis 127 99 (78%) 28 (22%)
Died 18 12 (67%) 6 (33%) OR 11.0 (3.6 - 33.0, P < 0.0001) aOR 11.1 (3.11 - 39.1, P < 0.0001)
Alive 117 99 (85%) 18 (15%)
aOR: adjusted odds ratio; OR: odds ratio; NLR: neutrophil-to-lymphocyte ratio.
Table 3.  ORs of Outcomes in LCR Groups on Day 1 and Day 7 of Treatment
Outcomes
Day 1
N LCR < 100 LCR > 101 Unadjusted odds (P value) aOR (P value)
Vent 60 17 (28%) 43 (72%) OR 2.5 (1.3 - 5.0, P = 0.01) aOR 2.5 (1.3 - 5.0, P = 0.009)
No vent 110 55 (50%) 55 (50%)
Upgrade 55 14 (26%) 41 (75%) OR 2.9 (1.47 - 6.1, P = 0.004) aOR 3.1 (1.5 - 6.3, P = 0.003)
No upgrade 115 58 (50%) 57 (50%)
Dialysis 10 3 (30%) 7 (70%) OR 1.8 (0.4 - 7.1, P = 0.63) aOR 1.8 (0.4 - 8.0, P = 0.44)
No dialysis 160 69 (43%) 91 (57%)
Died 20 10 (50%) 10 (50%) OR 0.71 (0.3 - 1.8, P = 0.62) aOR 0.8 (0.3 - 2.0, P = 0.60)
Alive 150 62 (41%) 88 (58%)
Outcomes
Day 7
N LCR < 100 LCR > 101 Unadjusted odds (P value) aOR (P value)
Vent 56 12 (21%) 44 (78%) OR 1.8 (0.8 - 4.0, P = 0.21) aOR 1.06 (0.43 - 2.64, P = 0.89)
No vent 76 25 (33%) 51 (68%)
Upgrade 50 10 (20%) 40 (80%) OR 2.0 (0.9 - 5.0, P = 0.16) aOR 1.16 (0.46 - 2.96, P = 0.74)
No upgrade 82 27 (33%) 55 (67%)
Dialysis 7 1 (14%) 6 (86%) OR 2.4 (0.3 - 21.0, P = 0.70) aOR 3.7 (0.2 - 55.6, P = 0.34)
No dialysis 125 36 (29%) 89 (71%)
Died 19 12 (63%) 7 (37%) OR 0.2 (0.06 - 0.47, P = 0.001) aOR 0.1 (0.01 - 0.30, P < 0.0001)
Alive 113 25 (22%) 88 (78%)
aOR: adjusted odds ratio; OR: odds ratio; LCR: lymphocyte-to-C-reactive protein ratio.
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hospital, the case fatality ratio in our study cannot reflect the 
true mortality of COVID-19. Lastly, the interpretation of our 
findings might be limited by the sample size. However, by ad-
justing the adult patients with confirmed disease, we believe 
that our population is the best representative of the real-world 
cohort.
Conclusions
A high LCR at presentation appears to predict an increased 
need for IMV and intensive care. A high NLR and low LCR, 
after COVID-19 therapy, predict higher odds of mortality. 
Large-scale studies are needed to validate our findings.
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